Argent Biopharma Limited (ASX: RGT) - Share Price
Current share price for RGT : $0.030 0.002 (6.25%)+
Argent Biopharma Limited (RGT, formerly MGC Pharmaceuticals Ltd) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It , is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. The company's proprietary delivery technologies enhance penetration across the blood-brain and alveolar-capillary barriers, supporting differentiated efficacy and composition-of-matter protection.
RGT General Information +
| ASX Code | RGT |
| Website | http://www.argentbiopharma.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 3 |
| RGT Share Price | $0.030 |
| Day High | $0.040 |
| Day Low | $0.030 |
| Last Close | $0.032 |
| RGT Share Price Movement | $0.00 ( 6.25% ) |
Prices as at 16:40, 29 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Argent Biopharma Limited (RGT) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Argent Biopharma Limited (RGT) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Argent Biopharma Limited (RGT) price-sensitive announcements
RGT - FDA-CVM Establish INAD File for CannEpil Veterinary Program
The U.S. FDA Center for Veterinary Medicine has established an Investigational New Animal
Argent Biopharma Limited (RGT)
26 Aug 2026 | 9:50 AM
26 Aug 2026 | 9:50 AM
RGT - US Veterinary Development Programme for CannEpil Commences
Argent BioPharma Limited has initiated a U.S. veterinary development programme for CannEpi
Argent Biopharma Limited (RGT)
6 Aug 2026 | 9:14 AM
6 Aug 2026 | 9:14 AM
RGT - CannEpil Global Licence Expands into Veterinary Healthcare
Argent BioPharma Ltd has expanded its CannEpil® licensing agreement to cover veterinary he
Argent Biopharma Limited (RGT)
31 Jul 2026 | 9:23 AM
31 Jul 2026 | 9:23 AM
RGT - Quarterly Activities/Appendix 4C Cash Flow Report
Argent Biopharma Limited announced key developments in its operations and financial status
Argent Biopharma Limited (RGT)
28 Jul 2026 | 8:25 AM
28 Jul 2026 | 8:25 AM
Argent Biopharma Limited (RGT) Recent ASX Announcements
RGT Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$7.77 | -$9.00 | -66.90% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$15.46 | -$27.00 | -43.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$17.63 | -$47.60 | 8,552.70% | 0.00 | 0.00 | 0.00% | 0.0% |
RGT Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $787M | 0.4454 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,563M | -0.7857 | 0.2462 | 0.9655 | 86.8930 | 69.7241 | 35.4737 | 0.00% | 1.63% | 1.93% |
| Argent Biopharma Limited (RGT) | $4M | -0.6685 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
RGT Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | -0.38 | 0.00 |
| Market | 0.34 | 13.70 | 1.16 | 0.78 |
| Sector | 0.65 | 30.70 | 2.70 | 1.49 |
RGT Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Andrew Chapman | Executive Director | 6 May 2026 |
| Mr Roby Reuven Zomer | Non-Executive Chairman, Non-Executive Director | 15 Feb 2016 |
| Mr Daniel Robinson | Non-Executive Director | 1 Dec 2023 |
Argent Biopharma Limited (RGT) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 15 Oct 2024 | ZOMER, Roby | Buy | Indirect Shares | 4,000,000 | $0.410 | $1,640,000.000 |
| 10 Sep 2024 | ZOMER, Roby | Buy | Indirect Shares | 1,258,500 | $0.400 | $503,400.000 |
| 6 May 2022 | ZOMER, Roby | Buy | Indirect Shares | 819,672 | $0.023 | $19,192.000 |
See all changes in directors' interest & trades for Argent Biopharma Limited (RGT) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
RGT Management
| Name | Position |
|---|---|
| Rowan Harland | Company Secretary |
RGT Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Argent Biopharma Limited (RGT). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 3,913,812 (15.06%) | Oak Capital Partners LLC |
| 3,405,016 (7.83%) | HSBC Custody Nominees (Australia) Limited |
RGT Calendar of Events
| Date | Event |
|---|---|
| 30 August 2027 | Report (Annual) |
| 30 August 2027 | Report (Prelim) |
| 26 February 2027 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
